All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.

The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your Lymphoma Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
SubtypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2019-06-24T10:46:20.000Z

Interpretation of R2-CHOP in large cell lymphoma

By Iqra Farooq, Nathan Fowler, Chan Cheah
Featured
Chan Cheah
Nathan Fowler
Jun 24, 2019
Share:

Bookmark this article

During ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Nathan Fowler, MD Anderson Cancer Center, Houston, US, and Chan Cheah, Sir Charles Gairdner Hospital, Nedlands, AU, about the latest trials in malignant lymphomas.

They discussed the results of trials investigating the use of CHOP chemotherapy and lenalidomide in newly diagnosed large cell lymphoma, and how two trials using these regimens had differing outcomes.

Prof Cheah spoke of the differences of these trials, such as the varying dosage of lenalidomide, and the positive and negative results of the two studies.

Interpretation of R2-CHOP in large cell lymphoma

More about...
Activated B-cell-likeAggressive B-cell lymphomasCHOPDiffuse large B-cell lymphomaE1912Germinal center B-cell-likeICML 2019LenalidomideRituximabROBUST

Understanding your specialty helps us to deliver the most relevant and engaging content.

Please spare a moment to share yours.

Please select or type your specialty

  Thank you

Related articles

Add bookmark

Lymphoma Hub Satellite Symposium 2019 | Chemo-free approaches for the treatment of lymphoid malignancies -  Professor Nathan Fowler

Professor Nathan Fowler, University of Texas MD Anderson Cancer Centre, Houston, US, presented the current state of...

Jul 29, 2019
Add bookmark

Lymphoma Hub Satellite Symposium 2019 | Chemo-free approaches for the treatment of lymphoid malignancies -  Professor Nathan Fowler

Professor Nathan Fowler, University of Texas MD Anderson Cancer...

Jul 29, 2019
Add bookmark

ICML 2019 | Comments on the addition of lenalidomide to R-CHOP in two studies

ICML 2019 | Comments on the addition of lenalidomide to R-CHOP in two studies

Jun 26, 2019
Add bookmark

ICML 2019 | Comments on the addition of lenalidomide to R-CHOP in two studies

ICML 2019 | Comments on the addition of lenalidomide to R-CHOP in two studies

Jun 26, 2019

Newsletter

Subscribe to get the best content related to lymphoma & CLL delivered to your inbox